UZ Brussel First to Treat Breast Cancer Patients with New Brainlab Deep Inspiration Breath Hold with Instant X-Ray Confirmation
Brainlab announced today that clinicians at UZ Brussel are the first to treat patients with the company’s new Deep Inspiration Breath Hold (DIBH)* technology designed to streamline image guided and surface guided radiation therapy (IGRT and SGRT) and deliver the highest quality of care for breast cancer patients. UZ Brussel is a university hospital at the Vrije Universiteit Brussel with 721 hospital beds and almost 4,000 employees. UZ Brussel successfully validated the technology and presented research at the Novalis Circle Symposium at ESTRO on May 8, 2022. The research demonstrates that Brainlab ExacTrac Dynamic® DIBH streamlines the process and increases positioning confidence through “on-the-fly” X-Ray confirmation. Internal anatomy verification at the breath hold level may increase confidence in dose sparing of critical structures like the heart.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005985/en/
CE-marked and FDA-cleared ExacTrac Dynamic enables the delivery of precision radiotherapy with surface and thermal tracking combined with real-time X-Ray monitoring. (Source: Brainlab)
Deep Inspiration Breath Hold is a well-established technique and standard of care in treating breast cancer with radiation therapy. When a patient takes a deep breath, the distance between the heart and the chest cavity is increased, reducing the risk of cardiac toxicity during breast cancer treatment. The new Brainlab technology takes traditional surface tracking methodology and augments it with a thermal signature, delivering a fourth dimension to reduce ambiguities otherwise associated with surface tracking systems. Adding synchronized X-ray images to the workflow increases accuracy and clinician confidence by incorporating insights derived from internal bony anatomy. Brainlab DIBH workflow is CE marked and FDA cleared.
“The incorporation of ‘on-the-fly’ X-Ray confirmation streamlines the process and delivers the confidence that the heart is outside of the treatment beam,” said Stefan Vilsmeier, President and CEO, Brainlab. “This solution delivers correlation between internal and external anatomy in one shot, revealing any misalignment that would otherwise remain undetected and could result in delivering excess dose to the heart. Partnering with UZ Brussel on new technologies demonstrates our combined interest in expanding personalized digital treatment innovation to other indications requiring high precision radiotherapy.”
“This is next generation technology and UZ Brussel is proud to work in close collaboration with our long-time partner Brainlab to validate and present our findings showing the superior speed, innovative postural patient positioning and seamless integration into our therapeutic radiation program,” said Prof. Mark de Ridder, Head of the Radiotherapy Department at UZ Brussel. “We’re excited to be the first to use this game changing positioning and breath hold control in breast cancer patients without skin marks. The positive effect on reducing cardiotoxicity on population level is significant. This becomes even more important with the increasing incorporation of neo-adjuvant chemotherapy and new HER2-directed monoclonal antibodies in the treatment strategy.”
In 2020, Brainlab installed new ExacTrac Dynamic Patient Positioning and Monitoring systems at UZ Brussel. The system’s deep integration with most linear accelerators enables thermal-surface triggered beam gating and repositioning. ExacTrac IGRT has always been the gold standard in frameless cranial, and high-precision spine stereotactic radiosurgery, enabling ablative treatments with minimal target margins.
With the introduction of the DIBH workflow, Brainlab is delivering the power of integrated IGRT to radiation therapy treatments for breast cancer patients. “We implemented this new workflow over the course of a few days,” explained Prof. Thierry Gevaert, Coordinator of the Medical Physics Radiotherapy Department at UZ Brussel. “The use of surface guided technology generates a more stable breathing curve compared to traditional surrogate marker technology. And the system’s X-Ray imaging allows for fast and low-dose internal anatomy verification at breath hold. The accurate triggering and correlation of anatomical verification with ExacTrac kV imaging will be the key differentiator to further margin reduction in breast radiotherapy.”
Please access the Dr. de Ridder presentation here and the Dr. Gevaert presentation here.
*Not yet commercially available in all countries. Please contact your sales representative.
About Brainlab
Brainlab is a digital medical technology pioneer founded in 1989 and headquartered in Munich. The company employs more than 2000 people in 25 locations around the globe. Brainlab serves physicians, medical professionals and their patients in over 6000 hospitals in 121 countries.
Brainlab creates software-driven medical solutions that digitize, automate and optimize clinical workflows for neurosurgery, spine, trauma, craniomaxillofacial (CMF), general and vascular surgery as well as radiotherapy and radiosurgery. Core products center around surgical navigation, radiotherapy, digital operating room integration, and information and knowledge exchange. The Brainlab open framework operating system will allow third parties to develop medical applications to further advance the field of spatial computing and mixed reality.
Brainlab is dedicated to creating an impact in healthcare. The company connects opportunities from emerging digital technologies to transform healthcare at scale and help improve the lives of patients worldwide. For more information, please visit Brainlab and follow on LinkedIn, Twitter, Facebook and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005985/en/
Contact information
Global
Bernadette Erwig
Manager Communication & PR
+49 89 99 1568 0
presse@brainlab.com
USA
Debbra Verard
Director, Marketing and Communications
+1 (708) 409-1343
presse@brainlab.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Expereo Appoints Noel Hamill as Chief Marketing Officer6.11.2025 11:00:00 EET | Press release
Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, today announces the appointment of Noel Hamill as its Chief Marketing Officer (CMO), a strategic hire to accelerate the company’s growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106364284/en/ Noel Hamill Hamill joins Expereo with over two decades of marketing leadership experience across global SaaS businesses and consumer brands, including EE and Ladbrokes, PG Forsta and most recently parcelLab, where he served as CMO. In his new role, Hamill will report directly to Ben Elms, CEO, and lead Expereo’s global marketing strategy with a sharp focus on driving growth, expanding market share, and scaling customer acquisition across enterprise and wholesale segments. His appointment underscores Expereo’s commitment to strengthening its brand presence and accelerating adoption of its expereoOne
IFF Benicarló Pioneers On-Site Green Hydrogen Production Facility for Sustainable Fragrance Ingredient Manufacturing6.11.2025 10:00:00 EET | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences, announced the installation of a nature-based hydrogen production facility at its Scent R&D and fragrance ingredients manufacturing plant in Benicarló, Spain. The site has partnered with Iberdrola, one of the world’s largest producers of renewable energy, to become the first in the fragrance industry to rely on renewable electricity for hydrogenation reactions used in manufacturing key fragrance ingredients. Aligned with the company’s commitment to Do More Good for people and planet, the site’s system can make 100 tons of clean hydrogen annually using renewable energy. It includes a built-in compressor to store hydrogen on-site — reducing the Life Cycle Assessment (LCA) of its products and supporting customers worldwide in achieving their decarbonization goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106888864/en/ Photo credit
Red Hat Introduces Confirmed Sovereign Support for European Union6.11.2025 10:00:00 EET | Press release
Red Hat, the world's leading provider of enterprise open source solutions, today announced Red Hat Confirmed Sovereign Support for the 27 member states of the European Union to address the critical strategic imperative for digital sovereignty in Europe. This new support offering is purpose-built to deliver dedicated EU-citizen-driven technical support from within the EU for Red Hat software subscriptions, providing a new level of verifiable local control over critical IT operations. More and more European business leaders are looking to digital sovereignty as a way to help drive economic differentiation in a global marketplace, as well as insulate operations from geopolitical dynamics and safeguard EU data, technology and operations. At the same time, these leaders want to further cloud infrastructure resiliency and AI innovation goals through strengthened supply chain transparency, jurisdictional security, compliance and autonomy. Red Hat Confirmed Sovereign Support is designed to add
Energy Transition Solutions Powered by Choice: Trilliant to Share Expertise and Knowledge with Utilities and Smart Cities at Enlit Europe 20256.11.2025 10:00:00 EET | Press release
Trilliant, a leading international provider of solutions for advanced metering infrastructure (AMI), smart grid, smart cities and IIoT, will be an exhibitor, presenter, and Silver Sponsor at Enlit Europe 2025. With product demonstrations on the exhibition floor and compelling presentations from thought leaders, Trilliant will highlight the importance of energy transition solutions, all powered by choice — that are flexible, scalable and interoperable. Taking place November 18- 20, 2025 in Bilboa, Spain, at the Bilbao Exhibition Centre (BEC), Enlit Europe 2025 is an event designed to connect industries, inspire action, and help Europe evolve into a dependable, decarbonised, and digitalised energy system. “As utilities and smart cities across Europe advance their energy transition journeys, they’re navigating a new wave of complexity from AI integration to the accelerating need for digitalisation,” said Jim Madej, President and CEO of Trilliant. “Meeting these goals requires solutions th
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA ® (ustekinumab) in Europe6.11.2025 09:00:00 EET | Press release
Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential. Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (ustekinumab) by the European Commission (EC) in April 2024. PYZCHIVA is currently approved for the treatment of adults and paediatric patients from the age of 6 years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease. “This is a significant milestone for patients living with autoimmune diseases as we are making a step forward in improving access to this important biologic medicine for healthcare systems, pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
